Background
Methods
Results
Category | Overall | < 70 years | ≥ 70 years | ||||
---|---|---|---|---|---|---|---|
N | % a | N | % a | N | % a | ||
Overall | 9359 | 6138 | 65.6 | 3221 | 34.4 | ||
Clinical stage | M1 | 658 | 7.0 | 377 | 6.1 | 281 | 8.7 |
Death certificate only notification | 183 | 2.0 | 36 | 0.6 | 147 | 4.6 | |
Study sample | 8518 | 91.0 | 5725 | 93.3 | 2793 | 86.7 | |
Laterality | available | 8508 | 99.9 | 5716 | 99.8 | 2792 | 100.0 |
unilateral | 8306 |
97.6
| 5600 |
98.0
| 2706 |
96.9
| |
synchronous bilateralb | 202 |
2.4
| 116 |
2.0
| 86 |
3.1
| |
Clinical stage | available | 7447 | 87.4 | 5312 | 92.8 | 2135 | 76.4 |
T1/2N0 | 4132 |
55.5
| 3011 |
56.7
| 1121 |
52.5
| |
T1/2N+ | 2379 |
31.9
| 1787 |
33.6
| 592 |
27.7
| |
T3/4N0 | 205 |
2.8
| 111 |
2.1
| 94 |
4.4
| |
T3/4N+ | 731 |
9.8
| 403 |
7.6
| 328 |
15.4
| |
Microscopically verified | 8482 | 99.6 | 5723 | 100.0 | 2759 | 98.8 | |
Morphology | available | 8477 | 99.5 | 5720 | 99.9 | 2757 | 98.7 |
invasive ductal | 5883 |
69.4
| 4053 |
70.9
| 1830 |
66.4
| |
invasive lobular | 1190 |
14.0
| 773 |
13.5
| 417 |
15.1
| |
mixed type | 654 |
7.7
| 465 |
8.1
| 189 |
6.9
| |
other | 750 |
8.8
| 429 |
7.5
| 321 |
11.6
| |
Histopathologic grade | available | 8216 | 96.5 | 5564 | 97.2 | 2652 | 95.0 |
1 | 610 |
7.4
| 405 |
7.3
| 205 |
7.7
| |
2 | 5232 |
63.7
| 3458 |
62.1
| 1774 |
66.9
| |
3/4 | 2374 |
28.9
| 1701 |
30.6
| 673 |
25.4
| |
HR expression | available | 7424 | 87.2 | 5048 | 88.2 | 2376 | 85.1 |
positivec | 6235 |
84.0
| 4152 |
82.3
| 2083 |
87.7
| |
negative | 1189 |
16.0
| 896 |
17.7
| 293 |
12.3
| |
HER2/neu expression | available | 5938 | 69.7 | 4051 | 70.8 | 1887 | 67.6 |
positived | 1466 |
24.7
| 1054 |
26.0
| 412 |
21.8
| |
negative | 4472 |
75.3
| 2997 |
74.0
| 1475 |
78.2
| |
Subtype based on immunohistochemical surrogates | HR and HER2/neu status available | 7197 | 84.5 | 4883 | 85.3 | 2314 | 82.8 |
‚HR positive‘ | 6235 |
86.6
| 4152 |
85.0
| 2083 |
90.0
| |
‚HER2/neu positive‘e | 368 |
5.1
| 278 |
5.7
| 90 |
3.9
| |
‚triple negative’f | 594 |
8.3
| 453 |
9.3
| 141 |
6.1
| |
Follow-up available | 8380 | 98.4 | 5634 | 98.4 | 2746 | 98.3 | |
years | years | years | |||||
Mean observation time | 10.3 | 10.4 | 10.3 |
Category/treatment | Sample | Overall | < 70 years | ≥ 70 years | |||
---|---|---|---|---|---|---|---|
N | % a | N | % a | N | % a | ||
Overall | study sample (8518) | 8518 | 5725 | 2793 | |||
Information on local treatment available | study sample (8518) | 6634 | 77.9 | 4548 | 79.4 | 2086 | 74.7 |
BCS | patients with information on surgery (6634) | 4245 |
64.0
| 3225 |
70.9
| 1020 |
48.9
|
Mastectomy | 2290 |
34.5
| 1300 |
28.6
| 990 |
47.5
| |
None | 99 |
1.5
| 23 |
0.5
| 76 |
3.6
| |
BCS | patients with T1/2N0 tumors and information on surgery (3435) | 244 |
7.1
| 134 |
5.4
| 110 |
11.7
|
BCS + RT | 2427 |
70.7
| 1925 |
77.3
| 502 |
53.2
| |
Mastectomy | 754 |
22.0
| 427 |
17.1
| 327 |
34.6
| |
BCS or mastectomy + RT | patients with T1/2N+ tumors and information on surgery (1995) | 1452 |
72.8
| 1162 |
78.2
| 290 |
57.0
|
Mastectomy + RT | patients with T3/4 tumors and information on surgery (755) | 350 |
46.4
| 232 |
55.6
| 118 |
34.9
|
Residual status available | patients with surgery (6535) | 5709 | 87.4 | 3972 | 87.8 | 1737 | 86.4 |
R0 | 5409 |
94.7
| 3773 |
95.0
| 1636 |
94.2
| |
R1/2 | 300 |
5.3
| 199 |
5.0
| 101 |
5.8
| |
CT information available | study sample (8518) | 6941 | 81.5 | 4961 | 86.7 | 1980 | 70.9 |
CT | patients with N+ or HR negative tumors and information on CT usage (3472) | 2429 |
70.0
| 2171 |
84.9
| 258 |
28.2
|
HT information available | study sample (8518) | 6740 | 79.1 | 4709 | 82.3 | 2031 | 72.7 |
HT | patients with HR positive tumors b and information on HT usage (5122) | 4356 |
85.0
| 3031 |
85.4
| 1325 |
84.3
|
TT information available | study sample (8518) | 4786 | 56.2 | 3375 | 59.0 | 1411 | 50.5 |
TT | patients with HER2/neu positive tumors c and information on TT usage (839) | 208 |
24.8
| 183 |
29.3
| 25 |
11.7
|
Category/treatment | N | 5-year CI | 10-year CI | p-value | |||
---|---|---|---|---|---|---|---|
PE | 95% CI | PE | 95% CI | ||||
Overall | 5311 | 10.4 | [9.6, 11.3] | 15.9 | [14.8, 17.0] | ||
Age | < 70 years | 3714 | 11.2 | [10.2, 12.3] | 17.2 | [16.0, 18.6] | < 0.001 |
≥ 70 years | 1597 | 8.7 | [7.4, 10.2] | 12.6 | [11.0, 14.5] | ||
Clinical stage | T1/2N0 | 2918 | 5.6 | [4.8, 6.5] | 9.4 | [8.3, 10.7] | < 0.001 |
T1/2N+ | 1613 | 14.8 | [13.1, 16.6] | 23.1 | [20.9, 25.5] | ||
T3/4N0 | 124 | 16.1 | [10.8, 24.2] | 23.5 | [16.7, 33.1] | ||
T3/4N+ | 409 | 26.9 | [22.9, 31.6] | 34.3 | [29.8, 39.6] | ||
missing | 247 | 9.0 | [6.0, 13.4] | 9.9 | [6.7, 14.5] | ||
Morphology | invasive ductal | 3690 | 10.9 | [10.0, 12.0] | 16.2 | [14.9, 17.5] | 0.075 |
invasive lobular | 758 | 9.7 | [7.8, 12.0] | 17.8 | [15.0, 21.1] | ||
mixed type | 459 | 9.0 | [6.7, 12.0] | 14.3 | [11.3, 18.2] | ||
other | 404 | 9.0 | [6.6, 12.3] | 11.1 | [8.3, 14.9] | ||
Histopathologic grade | 1 | 447 | 2.7 | [1.5, 4.7] | 5.9 | [3.9, 8.9] | < 0.001 |
2 | 3332 | 8.5 | [7.6, 9.5] | 13.9 | [12.6, 15.2] | ||
3/4 | 1497 | 16.8 | [15.0, 18.8] | 23.0 | [20.9, 25.4] | ||
missing | 35 | 17.6 | [8.4, 36.8] | 21.8 | [11.0, 43.1] | ||
HR expression | positivea | 4132 | 8.3 | [7.5, 9.2] | 14.0 | [12.9, 15.2] | < 0.001 |
negative | 775 | 22.8 | [20.0, 26.0] | 27.1 | [24.0, 30.5] | ||
missing | 404 | 9.0 | [6.6, 12.3] | 12.6 | [9.4, 16.8] | ||
HER2/neu expression | positiveb | 972 | 13.3 | [11.3, 15.6] | 21.7 | [18.9, 24.8] | < 0.001 |
negative | 2941 | 9.6 | [8.6, 10.7] | 14.0 | [12.7, 15.5] | ||
missing | 1398 | 10.2 | [8.7, 11.9] | 15.6 | [13.8, 17.7] | ||
Subtype based on immunohistochemical surrogates | ‚HR positive‘ | 4132 | 8.3 | [7.5, 9.2] | 14.0 | [12.9, 15.2] | < 0.001 |
‚HER2/neu positive‘c | 234 | 22.8 | [18.0, 28.9] | 28.0 | [22.4, 34.9] | ||
‚triple negative‘d | 376 | 23.2 | [19.3, 27.9] | 25.6 | [21.4, 30.5] | ||
missing | 569 | 12.7 | [10.3, 15.8] | 17.8 | [14.7, 21.6] | ||
BCS | T1/2N0 | 198 | 5.6 | [3.1, 10.0] | 7.7 | [4.4, 13.4] | |
BCS + RT | T1/2N0 | 2114 | 4.6 | [3.8, 5.6] | 8.4 | [7.2, 9.8] | |
Mastectomy | T1/2N0 | 606 | 9.1 | [7.1, 11.8] | 13.5 | [10.9, 16.7] | |
(BCS + RT or mastectomy) + HT | T1/2N0 HR positivea | 1749 | 3.9 | [3.1, 4.9] | 8.2 | [6.9, 9.8] | |
(BCS + RT or mastectomy) + CT | T1/2N0 HR negative | 277 | 12.3 | [9.0, 16.8] | 15.5 | [11.6, 20.6] | |
(BCS + RT or mastectomy) + HT (if HR positive) + CT (if HR negative) + TT | T1/2N0 HER2/neu positive | 73 | 2.7 | [0.7, 10.9] | 2.7 | [0.7, 10.9] | |
(BCS or mastectomy) + RT + CT + HT | T1/2N+ HR positivea | 554 | 12.0 | [9.6, 15.1] | 19.5 | [16.1, 23.7] | |
(BCS or mastectomy) + RT + CT | T1/2N+ HR negative | 156 | 28.4 | [22.1, 36.5] | 36.9 | [29.6, 46.0] | |
(BCS or mastectomy) + RT + CT + HT (if HR positive) + TT | T1/2N+ HER2/neu positive | 51 | 19.6 | [11.2, 34.4] | 21.9 | [12.9, 37.2] | |
MAST + RT + CT + HT | T3/4 HR positivea | 88 | 26.1 | [18.4, 37.2] | 34.0 | [24.7, 46.9] | |
MAST + RT + CT | T3/4 HR negative | 50 | 48.0 | [35.8, 64.3] | 52.2 | [39.8, 68.5] |
Category | Study sample | Patients with a local R0 resection, available follow-up and without recurrence within 3 months | |||
---|---|---|---|---|---|
N | % a | N | % a | ||
Overall | 8518 | 5311 | |||
Age | < 70 years | 5725 | 67.2 | 3714 | 69.9 |
≥ 70 years | 2793 | 32.8 | 1597 | 30.1 | |
Laterality | available | 8508 | 99.9 | 5307 | 99.9 |
unilateral | 8306 |
97.6
| 5198 |
97.9
| |
synchronous bilateral b | 202 |
2.4
| 109 |
2.1
| |
Clinical stage | available | 7447 | 87.4 | 5064 | 95.3 |
T1/2N0 | 4132 |
55.5
| 2918 |
57.6
| |
T1/2N+ | 2379 |
31.9
| 1613 |
31.9
| |
T3/4N0 | 205 |
2.8
| 124 |
2.4
| |
T3/4N+ | 731 |
9.8
| 409 |
8.1
| |
Microscopically verified | 8482 | 99.6 | 5311 | 100.0 | |
Morphology | available | 8477 | 99.5 | 5311 | 100.0 |
invasive ductal | 5883 |
69.4
| 3690 |
69.5
| |
invasive lobular | 1190 |
14.0
| 758 |
14.3
| |
mixed type | 654 |
7.7
| 459 |
8.6
| |
other | 750 |
8.8
| 404 |
7.6
| |
Histopathologic grade | available | 8216 | 96.5 | 5376 | 99.3 |
1 | 610 |
7.4
| 447 |
8.5
| |
2 | 5232 |
63.7
| 3332 |
63.2
| |
3/4 | 2374 |
28.9
| 1497 |
28.4
| |
HR expression | available | 7424 | 87.2 | 4907 | 92.4 |
positive c | 6235 |
84.0
| 4132 |
84.2
| |
negative | 1189 |
16.0
| 775 |
15.8
| |
HER2/neu expression | available | 5938 | 69.7 | 3913 | 73.7 |
positive d | 1466 |
24.7
| 972 |
24.8
| |
negative | 4472 |
75.3
| 2941 |
75.2
| |
Subtype based on immunohistochemical surrogates | HR and HER2/neu status available | 7197 | 84.5 | 4742 | 89.3 |
’HR positive‘ | 6235 |
86.6
| 4132 |
87.1
| |
‚HER2/neu positive‘e | 368 |
5.1
| 234 |
4.9
| |
‚triple negative‘f | 594 |
8.3
| 376 |
7.9
| |
Follow-up available | 8380 | 98.4 | 5311 | 100.0 | |
years | years | ||||
Mean observation time | 10.3 | 10.2 |
Category/treatment | N | 5-year CI | 10-year CI | p-value | |||
---|---|---|---|---|---|---|---|
PE | 95% CI | PE | 95% CI | ||||
Overall | 5311 | 5.4 | [4.8, 6.0] | 7.8 | [7.0, 8.6] | ||
Age | < 70 years | 3714 | 5.7 | [5.0, 6.5] | 8.5 | [7.6, 9.5] | 0.007 |
≥ 70 years | 1597 | 4.5 | [3.6, 5.6] | 6.1 | [4.9, 7.4] | ||
Clinical stage | T1/2N0 | 2918 | 2.8 | [2.3, 3.5] | 5.1 | [4.3, 6.1] | < 0.001 |
T1/2N+ | 1613 | 7.3 | [6.1, 8.7] | 10.3 | [8.8, 12.0] | ||
T3/4N0 | 124 | 8.9 | [5.0, 15.7] | 13.0 | [8.0, 21.1] | ||
T3/4N+ | 409 | 13.9 | [10.9, 17.7] | 15.1 | [12.0, 19.0] | ||
missing | 247 | 6.9 | [4.4, 11.0] | 7.8 | [5.1, 12.1] | ||
Morphology | invasive ductal | 3690 | 5.7 | [5.0, 6.5] | 8.1 | [7.2, 9.1] | 0.395 |
invasive lobular | 758 | 4.5 | [3.2, 6.3] | 8.0 | [6.2, 10.5] | ||
mixed type | 459 | 4.1 | [2.7, 6.4] | 6.0 | [4.1, 8.7] | ||
other | 404 | 5.5 | [3.7, 8.3] | 6.5 | [4.4, 9.5] | ||
Histopathologic grade | 1 | 447 | 1.3 | [0.6, 3.0] | 3.3 | [1.9, 5.9] | < 0.001 |
2 | 3332 | 4.3 | [3.6, 5.0] | 6.6 | [5.8, 7.6] | ||
3/4 | 1497 | 8.8 | [7.5, 10.3] | 11.4 | [9.9, 13.3] | ||
missing | 35 | 11.4 | [4.5, 29.2] | 15.5 | [6.7, 36.0] | ||
HR expression | positivea | 4132 | 4.1 | [3.6, 4.8] | 6.6 | [5.8, 7.4] | < 0.001 |
negative | 775 | 12.4 | [10.3, 15.0] | 15.2 | [12.8, 18.1] | ||
missing | 404 | 4.2 | [2.7, 6.8] | 5.2 | [3.4, 8.0] | ||
HER2/neu expression | positiveb | 972 | 7.1 | [5.7, 8.9] | 10.8 | [8.8, 13.2] | 0.004 |
negative | 2941 | 4.9 | [4.2, 5.7] | 6.9 | [6.0, 8.0] | ||
missing | 1398 | 5.1 | [4.1, 6.4] | 7.6 | [6.3, 9.2] | ||
Subtype based on immunohistochemical surrogates | ‘HR positive‘ | 4132 | 4.1 | [3.6, 4.8] | 6.6 | [5.8, 7.4] | < 0.001 |
‚HER2/neu positive‘c | 234 | 12.9 | [9.2, 18.0] | 16.2 | [11.8, 22.3] | ||
‘triple negative‘d | 376 | 12.0 | [9.1, 15.8] | 13.8 | [10.6, 17.9] | ||
missing | 569 | 6.7 | [4.9, 9.1] | 9.1 | [6.9, 11.9] | ||
BCS | T1/2N0 | 198 | 3.6 | [1.7, 7.4] | 4.9 | [2.3, 10.2] | |
BCS + RT | T1/2N0 | 2114 | 2.1 | [1.6, 2.9] | 4.4 | [3.5, 5.5] | |
Mastectomy | T1/2N0 | 606 | 4.8 | [3.4, 6.9] | 7.9 | [5.9, 10.5] | |
(BCS + RT or mastectomy) + HT | T1/2N0 HR positive a | 1749 | 1.7 | [1.2, 2.4] | 4.3 | [3.3, 5.5] | |
(BCS + RT or mastectomy) + CT | T1/2N0 HR negative | 277 | 6.5 | [4.2, 10.2] | 9.3 | [6.3, 13.7] | |
(BCS + RT or mastectomy) + HT (if HR positive) + CT (if HR negative) + TT | T1/2N0 HER2/neu positive | 73 | 0.0 | – | 0.0 | – | |
(BCS or mastectomy) + RT + CT + HT | T1/2N+ HR positive a | 554 | 5.8 | [4.2, 8.2] | 8.3 | [6.2, 11.2] | |
(BCS or mastectomy) + RT + CT | T1/2N+ HR negative | 156 | 12.9 | [8.5, 19.4] | 16.5 | [11.3, 24.1] | |
(BCS or mastectomy) + RT + CT + HT (if HR positive) + TT | T1/2N+ HER2/neu positive | 51 | 9.8 | [4.2, 22,7] | 9.8 | [4.2, 22,7] | |
MAST + RT + CT + HT | T3/4 HR positive a | 88 | 17.0 | [10.7, 27.1] | 17.0 | [10.7, 27.1] | |
MAST + RT + CT | T3/4 HR negative | 50 | 22.0 | [13.0, 37.3] | 26.2 | [16.3, 42.1] |
Category/treatment |
N
| 5-year CI | 10-year CI | p-value | |||
---|---|---|---|---|---|---|---|
PE | 95% CI | PE | 95% CI | ||||
Overall | 5311 | 7.2 | [6.5, 7.9] | 11.3 | [10.4, 12.3] | ||
Age | < 70 years | 3714 | 7.8 | [7.0, 8.7] | 12.5 | [11.4, 13.7] | < 0.001 |
≥ 70 years | 1597 | 5.8 | [4.7, 7.0] | 8.6 | [7.2, 10.2] | ||
Clinical stage | T1/2N0 | 2918 | 3.6 | [3.0, 4.4] | 6.0 | [5.1, 7.0] | < 0.001 |
T1/2N+ | 1613 | 10.8 | [9.4, 12.4] | 17.5 | [15.6, 19.7] | ||
T3/4N0 | 124 | 11.3 | [6.9, 18.6] | 16.6 | [10.9, 25.4] | ||
T3/4N+ | 409 | 19.6 | [16.1, 23.8] | 27.3 | [23.0, 32.4] | ||
missing | 247 | 3.3 | [1.6, 6.5] | 4.3 | [2.3, 7.9] | ||
Morphology | invasive ductal | 3690 | 7.6 | [6.8, 8.5] | 11.5 | [10.4, 12.7] | 0.085 |
invasive lobular | 758 | 6.6 | [5.1, 8.7] | 12.4 | [10.1, 15.4] | ||
mixed type | 459 | 6.3 | [4.5, 9.0] | 11.3 | [8.6, 15.0] | ||
other | 404 | 5.3 | [3.5, 8.0] | 7.0 | [4.8, 10.2] | ||
Histopathologic grade | 1 | 447 | 1.4 | [0.6, 3.0] | 3.9 | [2.3, 6.6] | < 0.001 |
2 | 3332 | 5.8 | [5.0, 6.6] | 9.8 | [8.7, 10.9] | ||
3/4 | 1497 | 12.1 | [10.5, 13.8] | 17.0 | [15.1, 19.1] | ||
missing | 35 | 9.0 | [3.0, 26.9] | 9.0 | [3.0, 26.9] | ||
HR expression | positive a | 4132 | 5.6 | [5.0, 6.4] | 10.0 | [9.0, 11.0] | < 0.001 |
negative | 775 | 15.9 | [13.5, 18.7] | 19.0 | [16.4, 22.1] | ||
missing | 404 | 6.3 | [4.3, 9.1] | 9.8 | [7.0, 13.8] | ||
HER2/neu expression | positive b | 972 | 9.1 | [7.4, 11.1] | 15.1 | [12.8, 17.8] | 0.001 |
negative | 2941 | 6.6 | [5.7, 7.5] | 9.8 | [8.7, 11.0] | ||
missing | 1398 | 7.2 | [6.0, 8.7] | 11.6 | [9.9, 13.5] | ||
Subtype based on immunohistochemical surrogates | ’HR positive‘ | 4132 | 5.6 | [5.0, 6.4] | 10.0 | [9.0, 11.0] | < 0.001 |
‚HER2/neu positive‘c | 234 | 15.9 | [11.8, 21.4] | 19.4 | [14.7, 25.5] | ||
‚triple negative‘d | 376 | 16.3 | [12.9, 20.5] | 18.7 | [15.0, 23.2] | ||
missing | 569 | 8.9 | [6.8, 11.5] | 12.6 | [10.0, 15.9] | ||
BCS | T1/2N0 | 198 | 3.1 | [1.4, 6.7] | 4.4 | [2.2, 8.7] | |
BCS + RT | T1/2N0 | 2114 | 3.0 | [2.4, 3.9] | 5.4 | [4.5, 6.6] | |
Mastectomy | T1/2N0 | 606 | 5.8 | [4.2, 8.0] | 8.2 | [6.2, 10.8] | |
(BCS + RT or mastectomy) + HT | T1/2N0 HR positive a | 1749 | 2.7 | [2.0, 3.6] | 5.2 | [4.2, 6.5] | |
(BCS + RT or mastectomy) + CT | T1/2N0 HR negative | 277 | 7.9 | [5.3, 11.9] | 9.2 | [6.3, 13.4] | |
(BCS + RT or mastectomy) + HT (if HR positive) + CT (if HR negative) + TT | T1/2N0 HER2/neu positive | 73 | 2.7 | [0.7, 10.9] | 2.7 | [0.7, 10.9] | |
(BCS or mastectomy) + RT + CT + HT | T1/2N+ HR positive a | 554 | 8.6 | [6.5, 11.3] | 15.4 | [12.2, 19.3] | |
(BCS or mastectomy) + RT + CT | T1/2N+ HR negative | 156 | 23.2 | [17.4, 31.0] | 30.7 | [23.9, 39.4] | |
(BCS or mastectomy) + RT + CT + HT (if HR positive) + TT | T1/2N+ HER2/neu positive | 51 | 13.7 | [6.8, 27.5] | 16.0 | [8.4, 30.5] | |
MAST + RT + CT + HT | T3/4 HR positive a | 88 | 14.8 | [8.9, 24.5] | 24.1 | [15.8, 36.8] | |
MAST + RT + CT | T3/4 HR negative | 50 | 40.0 | [28.3, 56.5] | 40.0 | [28.3, 56.5] |